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Abstract 
The present study was carried out in order to assess the quality of life and the psychological disorder symptoms of opium users
starting and following 4 weeks of detoxification program using buprenorphine. Results of the study showed that the differences 
between all of the subscales of the quality of life questionnaire were significant (P<0.001). Decrements in all of the psychological
disorder symptoms were also statistically significant (P<0.01). The results elicited the beneficial effects of the detoxification
programs using buprenorphine on quality of life and psychological disorder symptoms in opium -dependent men.   
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1. Introduction 
Opioid use by adolescents in the world and especially in Iran is on the rise and replacement therapy is an 
effective treatment. Drug abuse has many physical as well as psychological adverse effects. Craig and DiBuono 
(1996) showed that anxiety disorder is a prevalent psychopathology among those who use drugs for a long time. 
Brooner, King, Kidorf, Schmidt, and Bigelow (1997) found such psychological disorders as personality disorders, 
depression, as well as excessive boredom very common among their sample of 716 addicts, referring to a methadone 
therapy program. Darke, Kaye and Finlay-Jones (1998) recognized behavioral and psychological disorders like 
antisocial behavior and psychopathies in their sample of methadone therapy volunteers and later among their of 
heroin users (Darke, Williamson, Ross, Teeson, & Lynskey, 2004). Tidey, Mehl-Madrona, Higgins and Badger 
(1998) could find many behavioral and psychological disorders, such as suicide and violence impulses, paranoia, 
anxiety, as well as some other problems, among the cocaine users who had referred voluntarily to a treatment 
program. Antisocial behavior seen in many cases of cocaine and other drug users (Brooner et al., 1997; Tidey et al., 
1998), can be a major obstacle for treatment of drug dependence and cause the addict to return to the previous drug 
abuse behavior (Goldstein et al., 2001). Schmitz et al. (2000) observed poor psychiatric functioning, depressed 
mood and larger amounts of distress among their sample of depressed cocaine users. In fact, depression can be a 
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very common psychopathy, among the addicts (Teesson et al., 2004). Adamson, Todd, Sellman, Huriwai, and Porter  
(2006) identified many psychological disorders, in their sample of alcohol and drug users.  
Buprenorphine is a new replacement therapy that has been shown to be as effective as high dose methadone and 
may be better suited for the treatment of younger patients (Levy, Vaughan,  Angulo, & Knight, 2007). 
Buprenorphine is a partial agonist at the muopioid receptor and an antagonist at the kappa-opioid receptor. 
Buprenorphine blocks the euphoria of exogenous opioids, prevents opioid withdrawal and has decreased potential 
for abuse or overdose compared to methadone or other full mu-agonists (Fellin et al., 2002). Buprenorphine seems 
to be more effective in opioid-dependent patients affected by depression, probably due to the kappa opioid-receptors 
antagonist action, counteracting dysphoria, negativism and anxiety (Gerra, et al. 2006). 
Buprenorphine is a good means to combat horrible drug addictions that destroy lives and exact a wide range of 
social costs. Buprenorphine works on the same chemical receptors in the brain as heroin-like drugs. Rather than 
producing a high, it blocks cravings for narcotics. Therefore, one advantage of substance-abuse treatment using 
buprenorphine is that the drug may be made available through qualified primary-care physicians (physicians have to 
undergo required training to dispense). Addicts, especially adolescents, who might hesitate to seek treatment in 
traditional settings ought to feel more comfortable seeking help from a trusted family physician who can then work 
in concert with drug- abuse treatment providers. In most European countries, methadone treatment is provided to 
only 20 to 30 percent of persons who are addicted to opioids because of regulatory impediments and concerns about 
methadone safety (Auriacombe,  Fatseas, Dubernet, Daulouede, & Tignol, 2004). To address the unmet treatment 
need, buprenorphine was approved for use in France in 1996. All registered physicians are allowed to prescribe 
buprenorphine without any special education or licensing. As a result, approximately 80,000 patients per year – half 
of all opiate addicts – are treated with buprenorphine (Feroni, et al. 2005b). Pozinovsky, Grinshpoon, Margolis, 
Cohen and Rosca (2006) showed that compared with patients treated with clonidine, patients who received 
buprenorphine developed significantly less side-effects and related distress, and had higher senses of well-being, 
self-efficacy and social support. The findings suggest that buprenorphine is preferable for inpatient detoxification 
due to its side-effects profile and positive effects on well-being and psychosocial variables.  
Considering the important negative physical and psychosocial effects of the addiction, the current study was 
aimed at the quality of life and psychological symptoms of the opium using men, before and after detoxification 
with buperonorphine  
2. Methodology 
54 opium-dependent men received detoxification using buprenorphine for a period of 4 weeks. The participants 
ranged in age from 20 to 40 years. The mean age was 27.4 years.  
Quality of life and the psychological disorder symptoms were measured using the Quality of Life Questionnaire 
(SF-36) and Symptoms Checklist-90-Revised (SCL-90 -R), respectively.  
In many studies, quality of life has been assessed by using the SF-36 (Stewart, Hays, & Ware, 1988: Ware & 
Sherbourne, 1992). The SF-36 contains eight scales for assessing physical functioning, role limitations due to 
physical health, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, 
and mental health. The quality of life was used from Iranian version of the SF-36 questionnaire. This questionnaire 
had been translated to Persian and validated for Iranian population by Motamed, Ayatollahi, Zare and Sadeghi-
Hassanabadi (2005). In order to do this, they carried out a cross-sectional study of the staff of Shiraz Medical School 
during November 2001. Response rate was 83.6%. Internal consistency for 8 scales using Cronbach's alpha was 0.87 
(minimum recommended 0.85). Construct validity was acceptable as correlation between scales and some 
sociodemographic characteristics was significant. The correlation coefficient between 8 scales and related principal 
components was also acceptable.  
SCL-90 –R is a 90-item self-report symptom inventory designed to reflect the psychological symptom patterns of 
community, medical, and psychiatric respondents (Derogatis, Lipman, & Covi, 1973: Derogatis, Rickels, & Rock, 
1976). The SCL-90 -R items are as follows: anxiety, hostility, somatization, obsessive-compulsive, depression, 
paranoid ideation, interpersonal sensitivity, psychoticism, and phobic anxiety. The SCL-90 -R has adequate 
psychometric properties, with satisfactory internal consistency ranging from a low of 0.77 for psychoticism to a high 
of 0.90 for depression, while test-retest coefficients ranges from 0.68 for somatization to 0.83 for paranoid disorder 
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(Derogatis, 1994). The revised SCL-90-R was translated from English into Persian and standardized by Mirzai 
(1979). Her research yielded results that are consistent with those from the USA with regard to comparisons of 
reliability measures of concurrent validity, discriminate validity and construct validity. The Persian SCL-90 -R has 
adequate psychometric properties, with satisfactory internal consistency ranging from 0.77 for psychoticism to 0.90 
for depression, and test-retest coefficients ranged from 0.80 for somatization to 0.90 for paranoid disorder Mirzai 
(1979).
3-Results
Data from the questionnaires were analyzed using SPSS version 16. The mean scores of the subscales of the SF-
36 as well as the mean scores of the nine factors of  SCL-90-R before and after the detoxification using 
buprenorphine were compared through paired-t tests (Tables 1-2). 
UTable 1. Results of t-test analysis of quality of life subscales' scores before and after detoxification using buperonorphine (n = 54).
Variables Pre-treatment 
M (SD) 
Post-treatment 
M (SD) 
t-value
Physical functioning 31.03 (21.92) 81.20 (09.75) 7.38 
Role limitations due to physical 
health
25.00 (26.34) 62.96 (27.78) 5.72 
Bodily pain 40.81 (21.10) 75.74 (11.41) 10.67 
General health 42.01 (24.60) 22.68 (17.73) 6.23 
Vitality 40.27 (17.99) 67.77 (14.42) 8.58 
Social functioning 43.75 (24.48) 71.11 (19.54) 6.99 
Role limitations due to emotional 
problems 
38.83 (21.26) 66.77 (31.76) 3.59 
Mental health 44.44 (18.25) 68.44 (20.19) 6.30 
As shown in table 1, the differences between the SF-36 subscales mean scores before and after the detoxification 
by buperonorphine are statistically significant (P<.001). Thus, it can be concluded that quality of life of the subjects 
elicits a significant improvement after treatment with buperonorphine. 
UTable 2. Results of t-test analysis of Symptoms Checklist-90-Revised subscales' scores before and after detoxification using buperonorphine (n = 
54).
Variables Pre-treatment 
    M (SD) 
Post-treatment 
   M (SD) 
t-value
Somatization 1.32 (0.80) 0.64 (0.48) 5.40 
Obsessive-Compulsive 1.64 (0.74) 0.48 (0.47) 6.47 
Interpersonal Sensitivity 1.36 (0.65) 0.62 (0.46) 6.85 
Depression 1.40 (0.67) 0.70 (0.48) 6.16 
Anxiety 1.39 (0.82) 0.59 (0.43) 6.13 
Hostility 1.29 (0.82) 0.69 (0.58) 4.55 
Phobic Anxiety 0.94 (0.78) 0.58 (0.39) 3.23 
Paranoid Ideation 1.60 (0.81) 0.86 (0.80) 4.91 
Psychoticism 1.17 (0.71) 0.54 (0.47) 5.35 
As table 2 displays, the differences between the SCL-90 factors mean scores before and after the detoxification 
by buperonorphine are statistically significant. It means that psychological symptoms among opium -dependent 
participants decreased statistically from pre to post detoxification (P<.001). 
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The findings suggest that buprenorphine is preferable for inpatient detoxification due to its positive effects on 
satisfaction with quality of life and reduction of psychological symptoms among opium -dependent participants. 
Results of the previous studies indicated that buprenorphine prevents opioid withdrawal and has decreased potential 
for abuse or overdose compared to clonidine (Pozinovsky, et al, 2006) or methadone or other full mu-agonists 
(Fellin et al. 2002). Patients who received buprenorphine developed significantly less side-effects and related 
distress, and had higher senses of well-being, self-efficacy and social support. Buprenorphine may be better suited 
for the treatment of addicts, especially adolescents (Levy,  et al. 2007)  
4-Conclusion
These findings and the results of the present study suggest that buprenorphine is preferable for inpatient 
detoxification due to its side-effects profile and positive effects on quality of life and psychological health of the 
opioid-dependent patients. 
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